论文部分内容阅读
目的探讨缬沙坦联合苯磺酸左旋氨氯地平治疗高危高血压患者的临床疗效。方法选择常州市新北区春江人民医院2014年6月至2016年6月收治的201例高危高血压患者,随机分为治疗组(n=101)和对照组(n=100)。对照组采用苯磺酸左旋氨氯地平治疗,治疗组在对照组的基础上联合缬沙坦治疗。观察比较两组收缩压和舒张压水平、血钾和血肌酐浓度、SF-36评分及不良反应发生情况。结果治疗后,两组收缩压和舒张压水平均显著降低(P<0.05),且观察组低于对照组(P<0.05);治疗后4周,观察组收缩压和舒张压水平亦均显著低于对照组(P<0.05)。治疗后,两组血K+浓度、血肌酐浓度均显著降低(P<0.05),且观察组低于对照组(P<0.05);治疗后4周,观察组血K+浓度和对照组无差异(P>0.05),血肌酐浓度亦低于对照组(P<0.05)。两组SF-36评分均显著升高(P<0.05),且观察组显著高于对照组(P<0.05)。观察组不良反应率为5.94%,对照组为8.00%,两组比较无统计学意义(χ~2=1.612,P=0.880)。结论缬沙坦联合苯磺酸左旋氨氯地平治疗高危高血压临床疗效显著,安全性高,可以有效改善患者生活质量,值得推广应用。
Objective To investigate the clinical efficacy of valsartan combined with levamlodipine besylate in the treatment of high-risk hypertensive patients. Methods 201 high-risk hypertensive patients admitted to Chunjiang People’s Hospital of Xinbei District, Changzhou from June 2014 to June 2016 were randomly divided into treatment group (n = 101) and control group (n = 100). Control group levamlodipine besylate treatment group in the control group based on the combination of valsartan treatment. Systolic and diastolic blood pressure levels, serum potassium and serum creatinine concentrations, SF-36 scores and adverse reactions were observed and compared between the two groups. Results After treatment, systolic blood pressure and diastolic blood pressure in the two groups were significantly decreased (P <0.05), and the observation group was lower than the control group (P <0.05); 4 weeks after treatment, the systolic and diastolic blood pressure levels were also significantly Lower than the control group (P <0.05). After treatment, K + concentration and serum creatinine in both groups were significantly decreased (P <0.05), and the observation group was lower than the control group (P <0.05); 4 weeks after treatment, there was no difference between the K + concentration in the observation group and the control group P> 0.05), serum creatinine concentration also lower than the control group (P <0.05). SF-36 scores of both groups were significantly increased (P <0.05), and the observation group was significantly higher than the control group (P <0.05). Adverse reaction rate was 5.94% in the observation group and 8.00% in the control group. There was no significant difference between the two groups (χ ~ 2 = 1.612, P = 0.880). Conclusion Valsartan combined with levamlodipine besylate in the treatment of high-risk high blood pressure clinical efficacy is significant, high safety, can effectively improve the quality of life of patients, it is worth promoting the application.